Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 7.0% Today

What is Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ: AMLX) is a biopharmaceutical company concentrating on developing therapies for rare neurodegenerative diseases. The stock AMLX saw a significant bullish movement in the market today.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 7.0% on Jun 10, 2026 14:25

• The positive sentiment surrounding the company's presentation at ENDO 2026, where they discussed the burden of post-bariatric hypoglycemia (PBH) and the design of their Phase 3 LUCIDITY trial for avexitide, a promising GLP-1 receptor antagonist, could be a factor behind the bullish movement in AMLX stock.
• The grant of stock options to various directors, including George M. Milne Jr., Karen Firestone, Paul R. Fonteyne, and Bernhardt G. Zeiher, might have also influenced the positive market sentiment, indicating confidence in the company's future and potential growth.
• These stock options grants could be perceived by investors as a demonstration of commitment from the directors, aligning their interests with those of the company. This alignment likely contributed to boosting investor confidence in Amylyx Pharmaceuticals and driving the bullish movement in AMLX stock.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026

Amylyx Pharmaceuticals will present two posters at ENDO 2026 detailing the burden of post-bariatric hypoglycemia (PBH) in the U.S. and the participant-informed design of its Phase 3 LUCIDITY trial for avexitide. Avexitide, a first-in-class GLP-1 receptor antagonist, has received Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism, and aims to address the lack of FDA-approved therapies for PBH. The LUCIDITY trial is evaluating avexitide's efficacy and safety in reducing hypoglycemic events in PBH patients.

https://www.stocktitan.net/news/AMLX/amylyx-pharmaceuticals-announces-poster-presentations-at-endo-c3ynemkyt11c.html

Amylyx (NASDAQ: AMLX) director awarded 24,372 stock options at $14.31 strike

Amylyx Pharmaceuticals director George M. Milne Jr. was granted 24,372 stock options with an exercise price of $14.31 per share. These options expire on June 3, 2036, and will vest in full by June 4, 2027, or the next annual meeting, provided he continues his service to the company. This transaction is a grant of potential future ownership, not an immediate market purchase or sale of shares.

https://www.stocktitan.net/sec-filings/AMLX/form-4-amylyx-pharmaceuticals-inc-insider-trading-activity-a364b5663676.html

Amylyx (AMLX) director Karen Firestone receives 24,372 stock options grant

Amylyx Pharmaceuticals director Karen Firestone was granted 24,372 stock options with an exercise price of $14.31 per share. These options will vest by June 4, 2027, or the next annual meeting, contingent on her continued service. This transaction increases her direct option holdings to 24,372 shares.

https://www.stocktitan.net/sec-filings/AMLX/form-4-amylyx-pharmaceuticals-inc-insider-trading-activity-4b26954c325c.html

Amylyx (AMLX) director Paul Fonteyne receives grant of 24,372 stock options

Amylyx Pharmaceuticals director Paul R. Fonteyne was granted 24,372 stock options with an exercise price of $14.31 per share as compensation. These options will vest in full on the earlier of June 4, 2027, or the date of the next annual meeting, provided he remains with the company. Following this transaction, Fonteyne directly holds 24,372 stock options in Amylyx.

https://www.stocktitan.net/sec-filings/AMLX/form-4-amylyx-pharmaceuticals-inc-insider-trading-activity-c70831ec73e3.html

Amylyx (NASDAQ: AMLX) director receives 24,372 stock options grant

Amylyx Pharmaceuticals director Bernhardt G. Zeiher was granted 24,372 stock options with an exercise price of $14.31 per share, expiring on June 3, 2036. The options will vest in full on the earlier of June 4, 2027, or the next annual meeting, contingent on continuous service. This grant results in the director holding 24,372 derivative securities directly, reflecting a compensation-related award rather than an open-market transaction.

https://www.stocktitan.net/sec-filings/AMLX/form-4-amylyx-pharmaceuticals-inc-insider-trading-activity-28aacb11fd41.html

Trending Today

Gold ($XAU) Commodity Forecast: Down 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.2% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Down 27.7% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Down 5.2% Today

First Solar Inc. ($FSLR) Stock Forecast: Down 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Down 5.0% Today

FMC Corporation ($FMC) Stock Forecast: Down 5.4% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.2% Today

Cummins Inc. ($CMI) Stock Forecast: Down 5.0% Today

Newmont Mining Corporation ($NEM) Stock Forecast: Down 5.2% Today

Amylyx Pharmaceuticals Price History

21.04.2026 - AMLX Stock was up 5.5%

• The positive news of the peer-reviewed publication of Phase 2 trial data for AMX0035 in treating Wolfram syndrome likely fueled the bullish movement in AMLX stock. The results, showing stabilization or improvement in various health parameters, have increased investor confidence in the company's drug pipeline.
• The reaffirmation of a Buy recommendation by B of A Securities has further bolstered investor sentiment towards Amylyx Pharmaceuticals, suggesting optimism about the company's future performance.
• The filing of an amended Schedule 13G/A by Perceptive Life Sciences Master Fund, Ltd., reporting a significant passive stake in AMLX, may have also contributed to the bullish movement by signaling institutional investor interest and support in the company's potential growth prospects.

18.04.2026 - AMLX Stock was down 5.1%

• A bearish movement in AMLX stock today may be due to profit-taking by investors following a recent bullish trend.
• The positive announcement of Phase 2 trial results for AMX0035 in Wolfram syndrome might have already been factored into the stock price, resulting in limited upward momentum.
• Despite receiving a Buy recommendation from B of A Securities, it might not have been sufficient to override broader market sentiments or short-term trading strategies.
• Speculation surrounding the Phase 3 trial outcome for AVEXITIDE and a potential launch in 2027 could be fueling speculative actions, causing some investors to sell off their positions in the near term.

09.05.2026 - AMLX Stock was up 5.0%

• The increase in AMLX stock price today may be linked to the positive response following the news of directors receiving significant stock options, indicating a strong belief in the company's future performance.
• Ongoing stock option grants to key individuals within the company reflect a confidence in Amylyx Pharmaceuticals' long-term growth and success, which likely resonated positively with investors.
• Further adding to the optimistic sentiment, the announcement of a $6.5 million class action settlement for investors who acquired AMLX securities during a specific period could have provided stability and reassurance to the market, contributing to the upward movement in the stock.
• In summary, the combination of favorable internal developments like stock option grants and the resolution of legal matters through the settlement likely boosted investor confidence and drove the bullish trend in AMLX stock today.

15.04.2026 - AMLX Stock was down 5.6%

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

10.05.2026 - AMLX Stock was up 7.0%

• The positive sentiment surrounding the company's presentation at ENDO 2026, where they discussed the burden of post-bariatric hypoglycemia (PBH) and the design of their Phase 3 LUCIDITY trial for avexitide, a promising GLP-1 receptor antagonist, could be a factor behind the bullish movement in AMLX stock.
• The grant of stock options to various directors, including George M. Milne Jr., Karen Firestone, Paul R. Fonteyne, and Bernhardt G. Zeiher, might have also influenced the positive market sentiment, indicating confidence in the company's future and potential growth.
• These stock options grants could be perceived by investors as a demonstration of commitment from the directors, aligning their interests with those of the company. This alignment likely contributed to boosting investor confidence in Amylyx Pharmaceuticals and driving the bullish movement in AMLX stock.

29.03.2026 - AMLX Stock was down 5.1%

• The downward movement in AMLX stock today might be due to profit-taking by investors following several price target upgrades by different financial institutions. It is possible that traders decided to sell to secure profits after positive changes were made to the price targets.
• Despite the positive outlook from analysts and the excitement surrounding the Phase 3 LUCIDITY study data for avexitide, the market response today could indicate a short-term decline in the stock price.
• The reduction in the Co-CEO and Director's 2025 compensation compared to the previous year may also play a role in the negative sentiment towards the stock, potentially raising concerns about internal stability or performance expectations within the company.

28.03.2026 - AMLX Stock was down 5.2%

• The bearish movement in AMLX stock today could be attributed to the significant decrease in compensation for both Co-CEOs and Directors, Justin Klee and Joshua Cohen, as revealed in the recent SEC DEF14A filings. This unexpected decrease in executive pay may have raised concerns among investors about the company's financial performance or future prospects.
• Investors might be reacting to the upcoming Q3 2025 earnings preview, anticipating potentially disappointing financial results. The market sentiment could be influenced by expectations set by analysts and insiders' activities.
• Insider trading activities, hedge fund movements, and analyst ratings could have also contributed to the negative market sentiment surrounding AMLX stock, leading to the bearish movement observed today.

28.03.2026 - AMLX Stock was down 5.1%

• An increased price target for AMLX was influenced by a reduced expense forecast, potentially boosting investor confidence initially.
• However, concerns arose over the reduced compensation of the Co-CEO and Director in 2025, prompting doubts about the company's financial well-being and future prospects, leading to the bearish market movement.
• The impending Q3 2025 earnings preview may also be contributing to investor unease and stock selling pressure.
• In summary, despite positive adjustments to the price target, the news about reduced executive compensation and the upcoming earnings report could have dampened optimism, resulting in the decline of AMLX stock.

05.05.2026 - AMLX Stock was up 6.0%

• Key proposals at the Annual Meeting of Stockholders, including the election of new directors and the ratification of the independent accounting firm, likely boosted investor confidence in the company's governance and strategic direction.
• Analysts' optimism about Amylyx Pharmaceuticals' growth prospects, particularly in the post bariatric hypoglycemia (PBH) and neurodegeneration pipeline, may have attracted investors looking for long-term opportunities in the pharmaceutical industry.
• Progress in the pivotal Phase III LUCIDITY trial for avexitide, alongside potential future revenues and a positive estimated fair value per share, could have contributed to the bullish sentiment surrounding AMLX stock today.

12.04.2026 - AMLX Stock was down 5.2%

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

02.05.2026 - AMLX Stock was down 5.0%

• The recent downward trend in AMLX's stock may be linked to investors taking profits following a substantial price surge in the past year.
• While news of insider purchasing by director Karen Firestone was positive, market response may have been negative due to concerns about upcoming commercial launch obstacles and the requirement for additional capital for pipeline development.
• Uncertainties surrounding the success of the pivotal Phase III LUCIDITY trial for avexitide, a significant pipeline candidate, might also have contributed to the stock's decline.
• In conclusion, despite AMLX's strong long-term outlook with its innovative pipeline, short-term market sentiment and uncertainties could have influenced the current bearish movement.